ENZAMET Trifecta


ANZUP-led ENAZMET trial scooped the pool at the ACTA Trial of the Year Awards Ceremony. 

ENZAMET won the 2020 ACTA Trial of the Year Award, the ACTA STInG Award for Excellence in Trial Statistics and the Consumer Involvement Award. A fantastic achievement and the first trial to win all three awards!

Professor Ian Davis accepted the Trial of the Year Award, saying, "I’m honoured to be part of a study that has had such impact for men with metastatic prostate cancer. Professor Christopher Sweeney and I as co-chairs have been part of a talented and dedicated international team of researchers, staff, consumers, and most importantly, our trial participants. I could not be prouder than to have the ENZAMET Trial also acknowledged not only as Trial of the Year, but also for its excellence in trial statistics and consumer involvement.”

CTC staff were heavily involved in the design, coordination and analysis of this international trial and A/Prof Andrew Martin from the biostats team accepted the STInG Award for Excellence in Trial Statistics on behalf of his team.

Findings from the ENZAMET trial have shown that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone-sensitive prostate cancer, and men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in overall survival and a 60% improvement in progression-free survival, compared to men receiving standard treatment alone.

ENZAMET is a global collaborative investigator-initiated trial led by ANZUP and sponsored by the University of Sydney, in collaboration with the Canadian Cancer Trials Group, Dana-Farber Cancer Institute, and Cancer Trials Ireland (enrolling patients from Ireland and the United Kingdom). The University of Sydney NHMRC Clinical Trials Centre provided central study coordination. Astellas Pharma provided drug and financial support but was not involved in study conduct or data analysis.

ENZAMET continues to be recognised both nationally and internationally. Last year the trial featured in the ASCO main plenary session, and these practice changing results generated worldwide interest both through extensive media coverage and the medical community. In 2020 the achievements of this trial continued with ENZAMET featuring in ESMO’s Clinical Practice Guidelines for 2020. This along with as being named in the ASCO Annual Report on Progress Against Cancer earlier in the year as one of its Clinical Cancer Advances for 2020.

To read more about the ENZAMET study and the results please visit our webpage.